- 全部删除
您的购物车当前为空
Cenicriviroc Mesylate (TBR-652 Mesylate)是一种可口服的双重的CCR2/CCR5拮抗剂,具有抗炎和抗纤维化的作用,能够降低天冬氨酸与血小板比值指数(APRI)和无创肝纤维化指数(FIB-4),主要用于治疗肝纤维化。

Cenicriviroc Mesylate (TBR-652 Mesylate)是一种可口服的双重的CCR2/CCR5拮抗剂,具有抗炎和抗纤维化的作用,能够降低天冬氨酸与血小板比值指数(APRI)和无创肝纤维化指数(FIB-4),主要用于治疗肝纤维化。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,160 | In stock | |
| 5 mg | ¥ 1,490 | In stock | |
| 10 mg | ¥ 2,150 | In stock | |
| 25 mg | ¥ 4,290 | In stock | |
| 50 mg | ¥ 5,970 | In stock | |
| 100 mg | ¥ 8,220 | In stock | |
| 200 mg | ¥ 10,800 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,880 | In stock |
Cenicriviroc Mesylate 相关产品
| 产品描述 | Cenicriviroc Mesylate (TBR-652 Mesylate) is an orally administered dual CCR2/CCR5 antagonist exhibiting anti-inflammatory and anti-fibrotic effects. It reduces the Aspartate-to-Platelet Ratio Index (APRI) and Fibrosis-4 Index (FIB-4), primarily for treating liver fibrosis. |
| 靶点活性 | CCR5:0.29 nM, R5 HIV-1:0.024-0.08 nM (in PBMCs), R5 HIV-2:0.03-0.98 nM (in PBMCs), CCR2:5.9 nM |
| 体外活性 | Cenicriviroc Mesylate抑制R5 HIV-1(JR-FL)包膜介导的膜融合,IC50值为0.10 nM,但不影响X4 HIV-1(HXB2)包膜介导的膜融合,即使在浓度高达1,000 nM时也是如此。[5] |
| 体内活性 | 方法:Cenicriviroc Mesylate(15mg/kg,饮食中,12周)处理NASH小鼠模型,观察其治疗效果。 |
| 别名 | 西尼韦罗甲磺酸盐, TBR-652 Mesylate, TAK-652 Mesylate |
| 分子量 | 793.05 |
| 分子式 | C42H56N4O7S2 |
| CAS No. | 497223-28-6 |
| Smiles | CS(O)(=O)=O.CCCCOCCOc1ccc(cc1)-c1ccc2N(CC(C)C)CCC\C(=C/c2c1)C(=O)Nc1ccc(cc1)S(=O)Cc1cncn1CCC |
| 密度 | no data available |
| 颜色 | Yellow |
| 物理性状 | Solid |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 80 mg/mL (100.88 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容